|
rs10069690
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A previous genome-wide association study showed that hTERT rs10069690 and rs2736100 polymorphisms were associated with thyroid cancer risk.
|
31538903 |
2019 |
|
rs10069690
|
|
|
0.020 |
GeneticVariation |
BEFREE |
hTERT gene polymorphism at rs10069690C/T is associated with the risk and prognosis of thyroid cancer, but hTERT gene polymorphism at rs2736100G/T is not.
|
27472887 |
2016 |
|
rs1031583860
|
|
|
0.010 |
GeneticVariation |
BEFREE |
XRCC1 Arg280His and Arg194Trp were associated with thyroid cancer in Pakistani population.
|
29552790 |
2019 |
|
rs1032006770
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among them, the MET p.N375S and MLH1 p.V384D mutations, each was detected in two cases, and has rarely been found to be involved in thyroid cancer pathogenesis before.
|
28757314 |
2018 |
|
rs1042522
|
|
|
0.020 |
GeneticVariation |
BEFREE |
However, there was no significant association between p53 Arg72Pro po</span>lymorphism and thyroid cancer</span> risk under the other three genetic models (Pro vs. Arg: OR = 1.20, 95% CI 0.87-1.67, P = 0.262; ProPro vs. ArgArg: OR = 1.75, 95% CI 0.88-3.50, P = 0.113; ProPro/ArgPro vs. ArgArg: OR = 1.01, 95% CI 0.66-1.55, P = 0.968).
|
24037912 |
2014 |
|
rs1042522
|
|
|
0.020 |
GeneticVariation |
BEFREE |
It is evident from our study that Arg72Pro SNP of TP53 gene is connected with higher susceptibility to thyroid cancer especially in young age group, female gender, non-smokers and patients with elevated TSH levels, hence, implicated in thyroid carcinogenesis.
|
25835179 |
2015 |
|
rs1045642
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Possible roles of the xenobiotic transporter P-glycoproteins encoded by the MDR1 3435 C>T gene polymorphism in differentiated thyroid cancers.
|
23803106 |
2013 |
|
rs104894228
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Here, we show that depletion of RAF-1, a RAF family member with a poorly defined role in TC, decreases proliferation and increases apoptosis in TPC-1 cells and, less significantly, in cells harboring a BRAF(V600E) or HRAS(G13R) mutations, but without affecting ERK activation.
|
26265449 |
2015 |
|
rs1057519695
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We performed IHC for NRAS(Q61R) and direct sequencing for NRAS codon 61 in 4 thyroid cancer-derived cell lines and 98 follicular-patterned thyroid tumors that included 22 follicular thyroid adenomas (FTAs), 35 follicular thyroid carcinomas (FTCs), and 41 cases of nodular hyperplasia (NH).
|
26980032 |
2016 |
|
rs1057519834
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We performed IHC for NRAS(Q61R) and direct sequencing for NRAS codon 61 in 4 thyroid cancer-derived cell lines and 98 follicular-patterned thyroid tumors that included 22 follicular thyroid adenomas (FTAs), 35 follicular thyroid carcinomas (FTCs), and 41 cases of nodular hyperplasia (NH).
|
26980032 |
2016 |
|
rs1064795638
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, family members harboring the BAP1 c.1777C>T germline mutation developed other neoplastic disease including thyroid cancer.
|
26774355 |
2016 |
|
rs10951937
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We used multivariate unconditional logistic regression models to estimate associations between each SNP and thyroid cancer risk, as well as to directly estimate the genotype-environment interaction between each SNP and ionizing radiation.<b>Results:</b> Three SNPs were associated with increased risk of thyroid cancer and with thyroid microcarcinoma: <i>HUS</i> rs2708896, <i>HUS</i> rs10951937, and <i>MGMT</i> rs12769288.
|
29263185 |
2018 |
|
rs11077
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The results in our case-control study also confirmed that XPO5 rs11077 was significantly associated with onset of TC (GT/GG vs TT P = 0.035, adjusted odds ratio = 1.25, 95% confidence interval = 1.02-1.54).
|
28383405 |
2017 |
|
rs11214077
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We have previously shown that CS-associated SDHD variants G12S and H50R induce PTEN oxidation and nuclear accumulation in thyroid cancer.
|
28164237 |
2017 |
|
rs1126667
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Non-synonymous polymorphism (Gln261Arg) of 12-lipoxygenase in colorectal and thyroid cancers.
|
22864639 |
2012 |
|
rs1131691014
|
|
|
0.020 |
GeneticVariation |
BEFREE |
However, there was no significant association between p53 Arg72Pro po</span>lymorphism and thyroid cancer</span> risk under the other three genetic models (Pro vs. Arg: OR = 1.20, 95% CI 0.87-1.67, P = 0.262; ProPro vs. ArgArg: OR = 1.75, 95% CI 0.88-3.50, P = 0.113; ProPro/ArgPro vs. ArgArg: OR = 1.01, 95% CI 0.66-1.55, P = 0.968).
|
24037912 |
2014 |
|
rs1131691014
|
|
|
0.020 |
GeneticVariation |
BEFREE |
It is evident from our study that Arg72Pro SNP of TP53 gene is connected with higher susceptibility to thyroid cancer especially in young age group, female gender, non-smokers and patients with elevated TSH levels, hence, implicated in thyroid carcinogenesis.
|
25835179 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our findings not only reveal an epigenetic mechanism for BRAF V600E-promoted NIS silencing involving histone deacetylation at critical regulatory regions of the NIS promoter but also provide further support for our previously proposed combination therapy targeting major signaling pathways and histone deacetylase to restore thyroid gene expression for radioiodine treatment of thyroid cancer.
|
24243688 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study investigates the expression of CYP24A1 and the effect of BRAF(V600E) on its expression in thyroid cancer.
|
24382015 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associated with a marked drop in thyroperoxidase (29-fold) and pendrin (20-fold) expression and a considerable increase (five-fold) in GLUT-1 expression.
|
17854396 |
2008 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We developed an allele-specific real-time PCR method for the detection of BRAF(T1799A) in blood samples and studied prospectively blood samples from 193 patients with thyroid cancer (173 PTC, 20 non-PTC) attending for routine follow-up.
|
19850689 |
2009 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
|
30036146 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, this study has confirmed that the BRAF(T1799A) mutation confers cancer cells sensitivity to PLX4032 and demonstrated its specific potential as an effective and BRAF(T1799A) mutation-selective therapeutic agent for thyroid cancer.
|
21185263 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The presence of BRAF V600E mutation in FNAC material is always associated with the presence of TC.
|
26884114 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyroid carcinomas (PTCs) that are 80-90% of all thyroid cancers.
|
18310287 |
2008 |